Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab.
1/5 보강
[BACKGROUND] Glofitamab is a bispecific antibody engaging CD3 on T-cells and CD20 on B-cells.
APA
Ullmann M, Seipel K, et al. (2026). Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab.. Cancers, 18(6). https://doi.org/10.3390/cancers18060930
MLA
Ullmann M, et al.. "Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab.." Cancers, vol. 18, no. 6, 2026.
PMID
41899534
Abstract
[BACKGROUND] Glofitamab is a bispecific antibody engaging CD3 on T-cells and CD20 on B-cells. Glofitamab is approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma (R/R DLBCL). Lymphocyte-activation gene 3 (LAG3) and T-lymphocyte-associated protein 4 (CTLA4) are immune checkpoint receptors with inhibitory effects on T-cell activity. There are several common germline variants of both receptor genes.
[METHODS] Here, we evaluate clinical outcomes in R/R DLBCL patients treated with glofitamab according to the single-nucleotide polymorphisms rs870849 and rs231775.
[RESULTS] While there was no apparent association of genotype with glofitamab treatment outcomes, significant differences emerged in rs870849 carriers with extended progression-free and overall survival in homozygous T455, intermediate PFS and OS in heterozygous I455T, and short PFS and OS in homozygous I455 carriers.
[CONCLUSIONS] rs870849 may be a prognostic response marker in R/R DLBCL treated with glofitamab.
[METHODS] Here, we evaluate clinical outcomes in R/R DLBCL patients treated with glofitamab according to the single-nucleotide polymorphisms rs870849 and rs231775.
[RESULTS] While there was no apparent association of genotype with glofitamab treatment outcomes, significant differences emerged in rs870849 carriers with extended progression-free and overall survival in homozygous T455, intermediate PFS and OS in heterozygous I455T, and short PFS and OS in homozygous I455 carriers.
[CONCLUSIONS] rs870849 may be a prognostic response marker in R/R DLBCL treated with glofitamab.